Tag: Novartis
Spin-off from Novartis – Sandoz: How a paint factory transformed into a pharmaceutical company – News
Contents Sandoz is a traditional brand in the Swiss pharmaceutical industry. With the spin-off from Novartis, it will become independent again. Today’s Sandoz has nothing to do with the original…
Novartis: acquisition of Mycamine by Sandoz finalized
(CercleFinance.com) – Sandoz, the generics and biosimilars division of Novartis in the process of being spun off, says it has completed the acquisition of the worldwide trademark rights for the…
Novartis: green light for a Sandoz biosimilar for MS
(CercleFinance.com) – Sandoz, the generics and biosimilars division of Novartis in the process of being spun off, announces that the United States FDA has approved the biosimilar Tyruko (natalizumab-sztn), developed…
Generics division is spun off: Novartis sends Sandoz to the stock exchange
Generics division is spun off Novartis is going public with Sandoz 8/18/2023 8:58 am The Swiss pharmaceutical company Novartis is streamlining its business. This also includes the separation from the…
Novartis: Positive data for an Eylea biosimilar
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Novartis: positive data for an Eylea biosimilar
(CercleFinance.com) – Sandoz, a subsidiary of Novartis in the process of being spun off, announces the positive results of the Phase III efficacy and safety confirmation study MYLIGHT for its…
Novartis: Completes the acquisition of Chinook for $3.5 billion
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Novartis: completes the acquisition of Chinook for $3.5 billion
(CercleFinance.com) – Novartis announced today that it has completed the acquisition of Chinook Therapeutics, a Seattle-based biopharmaceutical company specializing in the discovery, development and commercialization of precision drugs for kidney…
Novartis: positive opinion for a biosimilar in MS
(CercleFinance.com) – Sandoz, the generics and biosimilars division of Novartis in the process of being spun off, announces that the CHMP of the European Medicines Agency recommends the marketing authorization…
Novartis: Positive opinion for a biosimilar in MS
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Novartis: Negative court decision on Entresto
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Novartis: negative court decision on Entresto
(CercleFinance.com) – Novartis announces that the US District Court in Delaware has issued a negative decision regarding the validity of a patent covering Entresto and combinations with sacubitril and valsartan,…